PMID- 29343971
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220311
IS  - 1178-6930 (Print)
IS  - 1178-6930 (Electronic)
IS  - 1178-6930 (Linking)
VI  - 11
DP  - 2018
TI  - Assessment of the cardiac safety between cetuximab and panitumumab as single 
      therapy in Chinese chemotherapy-refractory mCRC.
PG  - 123-129
LID - 10.2147/OTT.S149716 [doi]
AB  - OBJECTIVE: The cardiac safety of cetuximab and panitumumab, particularly as 
      single agents, has not been investigated extensively. This trial was designed to 
      specifically evaluate the cardiac safety of cetuximab and panitumumab as single 
      therapy in Chinese chemotherapy-refractory metastatic colorectal cancer (mCRC) 
      patients. PATIENTS AND METHODS: Sixty-one patients received cetuximab at an 
      initial dose of 400 mg/m(2) intravenously over 120 minutes on day 1 (week 1), 
      followed by a maintenance dose of 250 mg/m(2) intravenously over 60 minutes on 
      day 1 of each 7-day cycle. Forty-three patients received panitumumab at a dose of 
      6 mg/kg intravenously every 14 days. Routine laboratory tests and 
      electrocardiogram (ECG) were performed at baseline, during therapy and after the 
      treatment (4th and 10th months). The incidence of elevation of troponin I ultra 
      (TNI Ultra), abnormal ECGs, cardiac events and noncardiac adverse events (AEs) 
      were recorded and analyzed. RESULTS: The incidence of elevation of TNI Ultra 
      between the two groups had no significance (p=0.681), and TNI Ultra+ was observed 
      more frequently in patients with metastases to more than three organs and they 
      received fourth or above lines of chemotherapy. The most frequent abnormal ECG 
      manifestations were nonspecific ST changes and QTc prolongation in the two 
      groups. At 10 months after treatment, most of the abnormal ECG manifestations 
      were reversed. The most common cardiac AEs of cetuximab and panitumumab included 
      palpitations, dyspnea, chest pain and arrhythmias requiring treatment. Most of 
      the events were mild and transient. The incidence of cardiac AEs had no 
      significant difference between the two groups. Rash was still the most common 
      noncardiac AE in both groups. CONCLUSION: Cetuximab and panitumumab showed 
      favorable cardiac safety as single agents for Chinese chemotherapy-refractory 
      mCRC patients. But monitoring for cardiac AEs is still necessary throughout the 
      entire treatment process.
FAU - Tang, Xue-Miao
AU  - Tang XM
AD  - Department of Ultrasound and Electrocardiogram.
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine.
FAU - Chen, Hao
AU  - Chen H
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine.
AD  - Department of Clinical Laboratory, Sun Yat-Sen University Cancer Center, 
      Guangzhou.
FAU - Li, Qing
AU  - Li Q
AD  - Department of Ultrasound and Electrocardiogram.
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine.
FAU - Song, Yiling
AU  - Song Y
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine.
AD  - Department of Clinical Laboratory, Sun Yat-Sen University Cancer Center, 
      Guangzhou.
FAU - Zhang, Shuping
AU  - Zhang S
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine.
AD  - Department of Clinical Laboratory, Sun Yat-Sen University Cancer Center, 
      Guangzhou.
FAU - Xu, Xiao-Shuan
AU  - Xu XS
AD  - School of Laboratory Medicine, Guangdong Medical University.
FAU - Xu, Yiwei
AU  - Xu Y
AD  - Department of Clinical Laboratory, The Cancer Hospital of Shantou University 
      Medical College.
AD  - The Key Laboratory of Molecular Biology for High Cancer Incidence Coastal 
      Chaoshan Area, Shantou University Medical College, Guangdong, China.
FAU - Chen, Shulin
AU  - Chen S
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine.
AD  - Department of Clinical Laboratory, Sun Yat-Sen University Cancer Center, 
      Guangzhou.
LA  - eng
PT  - Journal Article
DEP - 20171228
PL  - New Zealand
TA  - Onco Targets Ther
JT  - OncoTargets and therapy
JID - 101514322
PMC - PMC5749385
OTO - NOTNLM
OT  - cardiac safety
OT  - cetuximab
OT  - colorectal cancer
OT  - panitumumab
OT  - targeted therapy
OT  - toxicity
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2018/01/19 06:00
MHDA- 2018/01/19 06:01
PMCR- 2017/12/28
CRDT- 2018/01/19 06:00
PHST- 2018/01/19 06:00 [entrez]
PHST- 2018/01/19 06:00 [pubmed]
PHST- 2018/01/19 06:01 [medline]
PHST- 2017/12/28 00:00 [pmc-release]
AID - ott-11-123 [pii]
AID - 10.2147/OTT.S149716 [doi]
PST - epublish
SO  - Onco Targets Ther. 2017 Dec 28;11:123-129. doi: 10.2147/OTT.S149716. eCollection 
      2018.